Israel Englander Alkermes Plc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Alkermes Plc. stock. As of the latest transaction made, Millennium Management LLC holds 824,352 shares of ALKS stock, worth $23.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

824,352

Holding current value

$23.7 Million

% of portfolio

0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $19 Million - $23.5 Million	824,352 New	824,352 $23.1 Million
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $11.2 Million - $13.8 Million	424,354 Added 179.53%	660,725 $17.9 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $33.2 Million - $40.8 Million	-1,422,660 Reduced 85.75%	236,371 $6.56 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $24.4 Million - $28.9 Million	-859,487 Reduced 34.13%	1,659,031 $51.9 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $23 Million - $26.4 Million	-909,367 Reduced 26.53%	2,518,518 $71 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $46.8 Million - $56 Million	2,133,877 Added 164.9%	3,427,885 $89.6 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $13.7 Million - $19.9 Million	623,268 Added 92.92%	1,294,008 $28.9 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $11.7 Million - $13.6 Million	444,593 Added 196.59%	670,740 $20 Million
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $2.32 Million - $2.81 Million	-100,535 Reduced 30.77%	226,147 $5.95 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $6.38 Million - $9.53 Million	297,020 Added 1001.35%	326,682 $7.6 Million
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $17 Million - $23.4 Million	-727,905 Reduced 96.08%	29,662 $915,000
Q2 2021 Aug 16, 2021	SELL	$18.78 - $25.15 $922,867 - $1.24 Million	-49,141 Reduced 6.09%	757,567 $18.6 Million
Q1 2021 May 17, 2021	BUY	$18.21 - $23.2 $9.32 Million - $11.9 Million	511,844 Added 173.59%	806,708 $15.1 Million
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $1.24 Million - $1.78 Million	80,713 Added 37.69%	294,864 $5.88 Million
Q3 2020 Nov 16, 2020	SELL	$16.16 - $20.66 $12.7 Million - $16.3 Million	-787,074 Reduced 78.61%	214,151 $3.55 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $11.8 Million - $17.2 Million	-884,217 Reduced 46.9%	1,001,225 $19.4 Million
Q1 2020 May 14, 2020	BUY	$13.06 - $21.24 $9.9 Million - $16.1 Million	757,722 Added 67.19%	1,885,442 $27.2 Million
Q4 2019 Feb 14, 2020	SELL	$17.29 - $21.74 $18.1 Million - $22.7 Million	-1,045,550 Reduced 48.11%	1,127,720 $23 Million
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $27.9 Million - $34.7 Million	1,430,765 Added 192.69%	2,173,270 $42.4 Million
Q2 2019 Aug 15, 2019	BUY	$21.47 - $37.33 $10.2 Million - $17.7 Million	473,123 Added 175.63%	742,505 $16.7 Million
Q2 2019 Aug 14, 2019	SELL	$21.47 - $37.33 $5.56 Million - $9.66 Million	-258,884 Reduced 49.01%	269,382 $10.7 Million
Q1 2019 May 14, 2019	SELL	$28.4 - $36.49 $11.2 Million - $14.3 Million	-393,139 Reduced 42.67%	528,266 $19.3 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $17.6 Million - $28.1 Million	629,953 Added 216.14%	921,405 $27.2 Million
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $7.76 Million - $9.28 Million	201,157 Added 222.78%	291,452 $12.4 Million
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $760,216 - $962,640	-18,743 Reduced 17.19%	90,295 $3.72 Million
Q1 2018 May 15, 2018	BUY	$53.61 - $67.26 $4.35 Million - $5.46 Million	81,231 Added 292.12%	109,038 $6.32 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $10.5 Million - $12.2 Million	-221,034 Reduced 88.83%	27,807 $1.52 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $12.2 Million - $13.5 Million	248,841	248,841 $12.7 Million

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account